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Apoptosis and proliferation are processes associated with the development and
progression of breast cancer. The sensitivity of tumour cells to the induction of
apoptosis depends on the balance between pro- and anti-apoptotic proteins.
The expression of Bak and Bcl-2 was examined using an immunohistochemical
method in 71 primary breast cancers. Furthermore, Bcl-2 and Bak were assessed
in the normal mammary gland as well as in benign mammary dysplasia adjacent
to breast cancer. Positive immunostaining for Bcl-2 was observed in 77.8% of
cases of normal breast epithelium (NBE), 93% of benign dysplasia without intra-
ductal proliferation (BBD) as well as in 94% of intraductal proliferative lesions of
the breast (BIPL). Expression of Bak was detected in 39% of cases of NBE, 45%
of BBD and in 67% of BIPL. In breast cancer Bcl-2 and Bak expression was found
in 83% and 70% of the cases studied, respectively. Increased Bcl-2 expression in
primary tumours significantly correlated with favourable prognostic factors, name-
ly pT1, G2 and lack of metastases to the regional lymph nodes (p < 0.01,
p < 0.03, p < 0.02, respectively). There were no relationships between Bak and
the clinicopathological features studied, but our results indicate changes in the
expression of Bak during breast cancer development and progression. It would
appear to be important to assess and compare pro- and anti-apoptotic proteins
between normal mammary gland, benign mammary dysplasia and the primary
tumours of breast cancer. This knowledge should be helpful in understanding
breast cancer development and progression.
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INTRODUCTION
The main group of genes controlling apoptosis is
the Bcl-2 family, which comprises both inhibitors
(Bcl-2, Bcl-Xl, Mcl-1) and promotors (Bax, Bak, Bad,
Bcl-Xs) [19]. Bcl-2 family members regulate mammary
gland development and homeostasis [6–8]. The ra-
tio of anti- and pro-apoptotic proteins regulates the
rate of cell death during ductal development, preg-
nancy and lactation as well as mammary gland invo-
lution. The Bcl-2 protein, apart from its well-known
inhibition of apoptosis, can also inhibit progression
of the cell cycle by delaying entry into the S phase
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and maintaining cells in the G0 phase [3, 17]. The
anti-apoptotic and anti-proliferative effects of Bcl-2
on the epithelial cells can diverge during breast can-
cer development [4]. Moreover, changes in the ex-
pression levels of anti- and pro-apoptotic proteins
influence breast cancer development and progres-
sion [14, 18]. Pro-apoptotic Bax and Bak heterodimer-
ise with anti-apoptotic Bcl-2 and Bcl-Xl and through
this process Bcl-2 could inhibit apoptosis, increase
the lifetime of invasive cells and induce clone selec-
tion and the metastatic process of breast cancer [10].
The purpose of the study was to evaluate the ex-
pression of the proteins involved in the regulation of
apoptosis (Bcl-2 and Bak) in primary breast cancer as
well as in the normal mammary gland and in benign
mammary dysplasia adjacent to breast cancer.
MATERIAL AND METHODS
This study comprised 71 women, who underwent
surgery for primary breast cancer in the years 2000–
–2002. The age of the patients ranged from 30 to
80 years and the mean age was 54.6 years. The patients
had not received any preoperative chemotherapy or
hormonotherapy. Tumour samples were collected im-
mediately after tumour removal, fixed in 10% buff-
ered formaldehyde solution and embedded in paraf-
fin blocks at 56oC. Histopathological examination, ac-
cording to the WHO classification of tumours [25],
was performed using standard haematoxylin-eosin
staining. Immunohistochemical studies were per-
formed according to Koda et al. [12, 13], using the
following antibodies: goat polyclonal Bak (Santa Cruz
Biotechnology, USA) at a 1:200 dilution and mouse
monoclonal Bcl-2 (Dako, Denmark) at a dilution 1:100.
The reactions were performed by the Labelled Strepta-
vidin Biotin (LSAB) technique (Dako). Appropriate im-
munohistochemical controls were carried out. The
evaluation of the immunostaining of Bak and Bcl-2
was analysed in 10 different tumour fields and the
mean percentage of tumour cells with positive stain-
ing was evaluated. The cut-off point for classifying
the sections examined as positive was 25% of posi-
tively stained cells for Bak and Bcl-2. Their expression
was also assessed in 18 normal breast tissues (NBE)
adjacent to the breast cancer, 29 cases of benign dys-
plasia without intraductal proliferative lesions (BBD)
and 18 cases of intraductal proliferative lesions (BIPL),
mainly including usual ductal hyperplasia.
The differences between Bak and Bcl-2 status and
the correlation with various clinicopathological fea-
tures (stage, grade of tumour and lymph node sta-
tus) were evaluated using the Mann-Whitney U test.
Statistical significance was assumed at p < 0.05.
Correlation coefficients were used to assess associa-
tions between the parameters studied.
RESULTS
In the study group of 71 women with primary
breast cancer at the time of diagnosis 36 (50.7%)
were without metastases to the regional lymph
nodes [N(–)] and 35 (49.3%) involved the regional
lymph nodes [N(+)]. Our studies included only inva-
sive ductal carcinomas, representing grades G2 and
G3 (49 and 22 cases, respectively) as well as the pT1
(43 cases) and pT2 (28 cases) stages.
Bcl-2 and Bak expression in the normal
mammary gland and in benign breast lesions
adjacent to breast cancer
Immunohistochemical analysis of NBE, BBD and
BIPL revealed cytoplasmic localisation and microgran-
ular staining for the Bcl-2 and Bak proteins. Strong
immunostaining for Bcl-2 was observed in 77.8% of
cases of NBE, 93% of BBD as well as in 94% of BIPL.
Bcl-2 expression in NBE, BBD and BIPL positively cor-
related with Bcl-2 expression in breast cancer. Weak
positive immunostaining for the Bak protein was ob-
served in 39% of NBE, 45% of BBD and 67% of BIPL.
Associations of Bcl-2 and Bak expression
in breast cancer with selected
clinicopathological features
The expression of Bcl-2 and Bak was detected in
83% and 70% of the breast cancers, respectively. In
the majority of cases Bcl-2 and Bak immunostaining
was cytoplasmic, similar to that reported for NBE, BBD
and BIPL, but in some tumours we also observed peri-
nuclear staining. Increased Bcl-2 expression in prima-
ry tumours significantly correlated with lack of me-
tastases to the regional lymph nodes [N(–); p < 0.02;
Table 1] as well as with the pT1 stage of the tumours
Table 1. Bcl-2 and Bak expression in breast cancer in re-
lation to lymph node status
N(–) (mean ± SD) N(+) (mean ± SD) Significance
(n = 36) (n = 35)
Bak (45.3 ± 26.8) Bak (50.2 ± 25.8) NS
Bcl-2 (65.8 ± 25.3) Bcl-2 (56.26 ± 24.1) p < 0.02
Mean ± SD — mean percentage of Bcl-2 or Bak-positive cells in 10 different tu-
mour fields (as described in Material and methods)
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(p < 0.01; Table 2) and grade G2 (p < 0.03; Table 3).
There were no relationships between Bak and the clini-
copathological features studied (Tables 1–3).
DISCUSSION
The expression of the Bcl-2 family of proteins
changes during mammary gland development. Bcl-2
is expressed in the non-pregnant and early pregnan-
cy female, but not in the lactating mammary gland
[15]. An increase in the expression of pro-apoptotic
Bak occurs during late pregnancy and lactation as well
as during apoptotic involution [22]. Bcl-2 levels in
normal breast epithelium undergo periodic changes
during the menstrual cycle and this protein is regu-
lated in a hormone-dependent manner within the
premenopausal breast [21].
Dysregulation of the balance between prolifer-
ation, differentiation and apoptosis in the normal
mammary gland can lead to breast cancer devel-
opment. The up-regulation of cell proliferation as
well as the down-regulation of apoptosis contrib-
ute to the accumulation of mutations, which lead
to the subsequent development of breast cancer
[15, 25]. It has been shown that a high apoptotic
rate is associated with a high grade of tumour, large
tumour size and with a shortened disease-free sur-
vival period [16].
There are many theories about the lack of activi-
ty of anti-cancer drugs in breast cancer. The disrup-
tion of the apoptotic pathways may be one of rea-
sons. We therefore decided to assess the expression
of those factors involved in apoptosis in the normal
mammary gland, benign mammary dysplasia and
primary cancer. The most significant findings of our
study are: 1) a positive correlation in the expression
of Bcl-2 between normal breast epithelium (NBE),
benign dysplasia without intraductal proliferation
(BBD) and intraductal proliferative lesions of the
breast (BIPL) and breast cancer; 2) increased expres-
sion of Bak in breast cancer compared to NBE and
BBD (70%, 39%, 45%, respectively); 3) a lack of dif-
ferences in Bak expression between breast cancer
and BIPL (70% and 67%, respectively); 4) an associa-
tion between expression of Bcl-2 and favourable
prognostic factors [pT1, G2 and N(–)]; 5) increased,
but not statistically significant, expression of Bak in
poorly differentiated cancers.
In the study of Ioachim et al. [9] Bcl-2 protein
was detected in 85.2% of benign hyperplastic lesions
of the mammary gland and 40% of breast cancers.
Table 3. Bcl-2 and Bak expression in breast cancer in relation to histological grade
Lymph node status, number of patients G2 (mean ± SD) G3 (mean ± SD) Significance
N(–) and N(+), n = 49 (G2), n = 22 (G3) Bak (44.9 ± 26.7) Bak (54.1 ± 24.7) NS
Bcl-2 (66.1 ± 21.9) Bcl-2 (50.1 ± 28.2) p < 0.03
N(+), n = 22 (G2), n = 13 (G3) Bak (48.9 ± 26.6) Bak (52.5 ± 25.4) NS
Bcl-2 (60.8 ± 21.1) Bcl-2 (48.5 ± 27.5) NS
N(–), n = 27 (G2), n = 9 (G3) Bak (41.6 ± 26.8) Bak (56.4 ± 24.9) NS
Bcl-2 (70.3 ± 22.1) Bcl-2 (52.2 ± 30.7) NS
Mean ± SD — mean percentage of Bcl-2 or Bak-positive cells in 10 different tumour fields (as described in Material and methods)
Table 2. Bcl-2 and Bak expression in breast cancer in relation to tumour size
Lymph node status, number of patients pT1 (mean ± SD) pT2 (mean ± SD) Significance
N(–) and N(+), n = 43 (pT1), n = 28 (pT2) Bak (47.1 ± 26.7) Bak (48.8 ± 26.1) NS
Bcl-2 (67.1 ± 23.3) Bcl-2 (51.8 ± 25.1) p < 0.001
N(+), n =15 (pT1), n = 20 (pT2) Bak (49.9 ± 27.9) Bak (50.5 ± 24.9) NS
Bcl-2 (58.7 ± 24.8) Bcl-2 (54.4 ± 23.9) NS
N(–), n = 28 (pT1), n = 8 (pT2) Bak (45.5 ± 26.4) Bak (48.8 ± 26.1) NS
Bcl-2 (71.6 ± 21.6) Bcl-2 (45.4 ± 28.2) p < 0.01
Mean ± SD — mean percentage of Bcl-2 or Bak-positive cells in 10 different tumour fields (as described in Material and methods)
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On the other hand, Bargou et al. [1] observed no
difference with regard to Bcl-2 (and Bcl-XL) expres-
sion between normal breast epithelium and breast
cancer tissue. Similarly to Bargou et al. [1], we found
no significant differences in the percentage of Bcl-2-
-positive cases between breast cancers (83%) and NBE
(77.8%), BBD (93%) and BIPL (94%). In the study by
Gee et al. [5] Bcl-2 was detected in 70% of breast
cancers. It has also been shown that Bcl-2-positive
patients had a better prognosis than Bcl-2-nega-
tive patients [11, 24, 26]. Rochaix et al. [20] sug-
gested that Bcl-2 and Bak expression were associ-
ated with a regulation of apoptosis in breast can-
cer. They found that Bcl-2 expression in tumours
was associated with a better differentiation of the
cancers (G1 — 100% of Bcl-2-positive tumours,
G2 — 81%, G3 — 60%), but there was no relationship
between Bak and tumour grade [20]. In the present
study an association was observed between tumour
differentiation and Bcl-2 expression — the mean
percentage of tumour cells with positive staining
for Bcl-2 was increased in grade G2 breast cancers.
In the study of Berardo et al. [2] high Bcl-2 expres-
sion was associated with favourable prognostic fac-
tors such as. ER positivity, low S phase fraction,
a lower number of positive lymph nodes and over-
all survival. Our findings confirm the results of Be-
rardo et al. [2] with regard to the favourable prog-
nostic significance of Bcl-2 expression in breast can-
cer. Moreover, we observed a positive correlation
between expression of Bcl-2 and ERa (unpublished
data). On the other hand, our observations are not
concordant with the results of Sierra et al. [23]
which showed that the over-expression of Bcl-2
correlated with lymph node involvement.
In the present study we observed an increased
expression of pro-apoptotic Bak in breast cancer com-
pared with NBE and BBD. On the other hand, we did
not find any differences in Bak expression between
breast cancer and BIPL. Our results indicate that over-
expression of pro-apoptotic proteins could contrib-
ute to an increase in cell turnover and breast cancer
development and progression, but we suggest that
further studies should be carried out to fully assess
Bak expression in breast cancer progression.
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